110
Participants
Start Date
February 10, 2016
Primary Completion Date
November 11, 2024
Study Completion Date
November 11, 2024
VIP152 (BAY 1251152)
The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
VIP152 (BAY 1251152) 30 mg
30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
Keytruda
200 mg IV fixed dose once every 3 weeks of a 21 day cycle
VIP152 (BAY 1251152) 15 mg
The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
Memorial Sloan Kettering Cancer Center, New York
Maryland Oncology Hematology, Silver Spring
START Madrid- Fundación Jiménez Diaz, Madrid
Sarah Cannon Research Institute, Nashville
Norton Cancer Institute, Louisville
University of Cincinnati Medical Center, Cincinnati
Avera Health, Sioux Falls
Highlands Oncology Group, Springdale
University of Texas MD Anderson Cancer Center, Houston
NEXT Oncology, San Antonio
NEXT Oncology, Austin
Oregon Health and Science University, Portland
Willamette Valley Cancer Institute, Eugene
Oncocentro, Viña del Mar
Centro de Investigaciones Clínicas Viña del Mar, Viña del Mar
John Theurer Cancer Center, Hackensack
Vincerx Pharma, Inc.
INDUSTRY